Expert Interview
Discussing the recently presented clinical case study from uniQure’s Phase I/IIa GenTLE trial evaluating AMT-260, an investigational gene therapy candidate for refractory mesial temporal lobe epilepsy (MTLE).
Ticker(s): QUREInstitution: Shiraz University of Medical Sciences / Thomas Jefferson University
-
Epileptologist and physician-researcher with specialized training in epilepsy and clinical neurophysiology, including invasive intracranial EEG monitoring
-
Leads a multidisciplinary epilepsy care and surgery program established in 2008 in Iran, providing advanced diagnostic and surgical treatment options for patients with refractory epilepsy
-
Primary research focus includes prognostic factors and outcomes in epilepsy surgery, psychogenic non-epileptic seizures, and idiopathic (genetic) generalized epilepsies; has published over 130 peer-reviewed papers and 10 books on epilepsy-related topics
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
